General
Preferred name
PASIREOTIDE
Synonyms
SOM 230 ()
SOM 320 ()
Pasireotide Acetate ()
Signifor ()
Pasireotide (acetate) ()
Pasireotide (L-aspartate salt) ()
Pasireotide (ditrifluoroacetate) ()
PASIREOTIDE DIASPARTATE ()
SOM230 (acetate) ()
SOM230 L-aspartate ()
SOM230 ditrifluoroacetate ()
Pasireotide TFA salt ()
P&D ID
PD009554
CAS
396091-76-2
396091-73-9
396091-77-3
Tags
available
drug
Drug Status
approved
Drug indication
Cushing disease
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ROE
Pasireotide is eliminated mostly by hepatic clearance (biliary excretion)(about 48%) with some minor renal clearance (about 7.63%).; ;
DESCRIPTION
Cyclic peptide analog of somatostatin. This compound is represented on ChEMBL with slightly different stereochemistry by CHEMBL3039583.
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
1
Compound Sets
13
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
Mcule NIBR MoA Box Subset
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
28
Molecular Weight
1046.5
Hydrogen Bond Acceptors
11
Hydrogen Bond Donors
9
Rotatable Bonds
17
Ring Count
8
Aromatic Ring Count
6
cLogP
3.37
TPSA
281.2
Fraction CSP3
0.33
Chiral centers
7.0
Largest ring
18.0
QED
0.06
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Somatostatin Receptor
SSTR1, SSTR2, SSTR3, SSTR5
Pathway
GPCR/G protein
Neuronal Signaling
Member status
member
MOA
Somatostatin SRIF1B (sst5) inhibitor
somatostatin receptor agonist
Indication
Cushing's syndrome, acromegaly
Biosynthetic Origin
Peptide (Ribosomal)
Therapeutic Indication
Cushing's Syndrome
Therapeutic Class
Hormone Therapy
Source data
